Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which chemo works best for esophageal cancer? new trial aims to find out

NCT ID NCT02359968

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two chemotherapy regimens (FOLFOX and CarboP-pacliT) given with radiation before surgery for esophageal or junction cancer. 106 patients were enrolled to see which treatment leads to better tumor removal and fewer serious complications. The goal is to help doctors choose the best approach for this type of cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FOLFOX (fluorouracil, oxaliplatin, folinic acid) and CarboP-pacliT (carboplatin, paclitaxel)
What this could lead to
If this trial succeeds, it could show which chemotherapy combination works best before surgery for esophageal cancer, helping doctors choose the most effective treatment.
What could go wrong
This is a phase 2 trial with only 106 participants, so results may not apply to everyone. Both treatments have side effects, and the study may not find a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

106 people

The number who actually took part.

Started

Feb 2015

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Resectable and operable esophageal cancer located under the carena (beyond 25 cm from the incisors) or junctional cancer (Siewert I or II) * Invasive adenocarcinoma or squamous cell type (to stick to the population included in the CROSS trial) * Patient who present with: * stage IIA (T3N0M0) * stage IIB (T1 N1 M0 or T2 N1 M0), * stage III (T3 N1 M0 or T4 N0 N1 M0) tumors * ECOG performance status 0, 1 or 2 * Patient eligible for preoperative chemoradiation with either fluorouracil- oxaliplatin-folinic acid, or Paclitaxel-carboplatin * Age ≥ 18 * Peripheral neuropathy ≤ NCI-CTC grade 1 * Adequate bone marrow reserve, normal renal and liver functions: * Neutrophil count ≥ 1500/mm3 * Platelet count ≥ 100 000/mm3 * Hemoglobin ≥ 10 g/dl (after transfusion, if necessary) * Creatinin \< 15mg/L * Clearance of creatinin (Cockcroft formulae) ≥ 60 ml/mn * Prothrombin time ≥ 60% * ASAT-ALAT ≤2.5 x ULN * Total bilirubin \< 1.5 x ULN * Albumin greater the lower limit of normal * Start of treatment within 28 days after randomization * Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential * Patient covered by government health insurance * Patient who provide a signed written informed consent form Exclusion Criteria: * Patient who present with stage I or stage IIA (including T2 N0 M0) or stage IV * Patient who present with common contraindications for surgery related to patient status * Patient who present with common contraindications for surgery related to disease extension * Patient who present with common contraindication to radiochemotherapy with either fluorouracile-cisplatin or with paclitaxel-carboplatin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms gastroesophageal cancer gastroesophageal junction adenocarcinoma neoplasm of esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal neoplasms Gastro esophageal junction cancer

Contacts and locations

Locations

  • CH Lyon sud

    Pierre-Bénite, France

  • CHU Bordeaux

    Bordeaux, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital La Timone

    Marseille, France

  • Hôpital Nord

    Marseille, France

  • ICM - Val d'Aurelle

    Montpellier, France

  • ICO Paul Papin

    Angers, France

  • ICO René Gauducheau

    Saint-Herblain, France

  • University Hospital of Lille

    Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.